High Risk of Heart Tumors after COVID-19
Author:
Mitrofanova Lubov1, Makarov Igor1ORCID, Goncharova Ekaterina1, Makarova Taiana1, Starshinova Anna1, Kudlay Dmitry23ORCID, Shlaykhto Evgeny1
Affiliation:
1. Almazov National Medical Research Centre, 197341 St. Petersburg, Russia 2. Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia 3. Institute of Immunology, 115478 Moscow, Russia
Abstract
An emergence of evidence suggests that severe COVID-19 is associated with an increased risk of developing breast and gastrointestinal cancers. The aim of this research was to assess the risk of heart tumors development in patients who have had COVID-19. Methods: A comparative analysis of 173 heart tumors was conducted between 2016 and 2023. Immunohistochemical examination with antibodies against spike SARS-CoV-2 was performed on 21 heart tumors: 10 myxomas operated before 2020 (the control group), four cardiac myxomas, one proliferating myxoma, three papillary fibroelastomas, two myxofibrosarcomas, one chondrosarcoma resected in 2022–2023. Immunohistochemical analysis with antibodies against CD34 and CD68 was also conducted on the same 11 Post-COVID period heart tumors. Immunofluorescent examination with a cocktail of antibodies against spike SARS-CoV-2/CD34 and spike SARS-CoV-2/CD68 was performed in 2 cases out of 11 (proliferating myxoma and classic myxoma). Results: A 1.5-fold increase in the number of heart tumors by 2023 was observed, with a statistically significant increase in the number of myxomas. There was no correlation with vaccination, and no significant differences were found between patients from 2016–2019 and 2021–2023 in terms of gender, age, and cardiac rhythm dis-orders. Morphological examination revealed the expression of spike SARS-CoV-2 in tumor cells, endothelial cells, and macrophages in 10 out of 11 heart tumors. Conclusion: The detection of SARS-CoV-2 persistence in endothelium and macrophages as well as in tumor cells of benign and malignant cardiac neoplasms, the increase in the number of these tumors, especially cardiac myxomas, after the pandemic by 2023 may indicate a trend toward an increased risk of cardiac neoplasms in COVID-19 patients, which re-quires further research on this issue and a search for new evidence.
Funder
Ministry of Science and Higher Education of the Russian Federation
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference70 articles.
1. The COVID Heart—One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks;Abbasi;JAMA,2022 2. Long-term cardiovascular outcomes of COVID-19;Xie;Nat. Med.,2022 3. Cardiovascular disease in SARS-CoV-2 infection;Sato;Clin. Transl. Immunol.,2021 4. Makarov, I., Mayrina, S., Makarova, T., Karonova, T., Starshinova, A., Kudlay, D., and Mitrofanova, L. (2023). Morphological Changes in the Myocardium of Patients with Post-Acute Coronavirus Syndrome: A Study of Endomyocardial Biopsies. Diagnostics, 13. 5. Mitrofanova, L.B., Makarov, I.A., Gorshkov, A.N., Runov, A.L., Vonsky, M.S., Pisareva, M.M., Komissarov, A.B., Makarova, T.A., Li, Q., and Karonova, T.L. (2023). Comparative Study of the Myocardium of Patients from Four COVID-19 Waves. Diagnostics, 13.
|
|